Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Article
  • Published:

Variants with large effects on blood lipids and the role of cholesterol and triglycerides in coronary disease

Abstract

Sequence variants affecting blood lipids and coronary artery disease (CAD) may enhance understanding of the atherogenicity of lipid fractions. Using a large resource of whole-genome sequence data, we examined rare and low-frequency variants for association with non-HDL cholesterol, HDL cholesterol, LDL cholesterol, and triglycerides in up to 119,146 Icelanders. We discovered 13 variants with large effects (within ANGPTL3, APOB, ABCA1, NR1H3, APOA1, LIPC, CETP, LDLR, and APOC1) and replicated 14 variants. Five variants within PCSK9, APOA1, ANGPTL4, and LDLR associate with CAD (33,090 cases and 236,254 controls). We used genetic risk scores for the lipid fractions to examine their causal relationship with CAD. The non-HDL cholesterol genetic risk score associates most strongly with CAD (P = 2.7 × 10−28), and no other genetic risk score associates with CAD after accounting for non-HDL cholesterol. The genetic risk score for non-HDL cholesterol confers CAD risk beyond that of LDL cholesterol (P = 5.5 × 10−8), suggesting that targeting atherogenic remnant cholesterol may reduce cardiovascular risk.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Relationship between the effect of sequence variants on non-HDL cholesterol and their effect on risk of coronary artery disease.

Similar content being viewed by others

References

  1. Barter, P.J. et al. Effects of torcetrapib in patients at high risk for coronary events. N. Engl. J. Med. 357, 2109–2122 (2007).

    Article  CAS  PubMed  Google Scholar 

  2. Schwartz, G.G. et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N. Engl. J. Med. 367, 2089–2099 (2012).

    Article  CAS  PubMed  Google Scholar 

  3. HPS2-THRIVE Collaborative Group. Effects of extended-release niacin with laropiprant in high-risk patients. N. Engl. J. Med. 371, 203–212 (2014).

  4. Peloso, G.M. et al. Association of low-frequency and rare coding-sequence variants with blood lipids and coronary heart disease in 56,000 whites and blacks. Am. J. Hum. Genet. 94, 223–232 (2014).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Lange, L.A. et al. Whole-exome sequencing identifies rare and low-frequency coding variants associated with LDL cholesterol. Am. J. Hum. Genet. 94, 233–245 (2014).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Jørgensen, A.B., Frikke-Schmidt, R., Nordestgaard, B.G. & Tybjærg-Hansen, A. Loss-of-function mutations in APOC3 and risk of ischemic vascular disease. N. Engl. J. Med. 371, 32–41 (2014).

    Article  PubMed  Google Scholar 

  7. TG and HDL Working Group of the Exome Sequencing Project, National Heart, Lung, and Blood Institute. Loss-of-function mutations in APOC3, triglycerides, and coronary disease. N. Engl. J. Med. 371, 22–31 (2014).

  8. Do, R. et al. Exome sequencing identifies rare LDLR and APOA5 alleles conferring risk for myocardial infarction. Nature 518, 102–106 (2015).

    Article  CAS  PubMed  Google Scholar 

  9. Brown, M.S. & Goldstein, J.L. A receptor-mediated pathway for cholesterol homeostasis. Science 232, 34–47 (1986).

    Article  CAS  PubMed  Google Scholar 

  10. Holmes, M.V. et al. Mendelian randomization of blood lipids for coronary heart disease. Eur. Heart J. 36, 539–550 (2015).

    Article  CAS  PubMed  Google Scholar 

  11. Do, R. et al. Common variants associated with plasma triglycerides and risk for coronary artery disease. Nat. Genet. 45, 1345–1352 (2013).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Voight, B.F. et al. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet 380, 572–580 (2012).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Varbo, A. et al. Remnant cholesterol as a causal risk factor for ischemic heart disease. J. Am. Coll. Cardiol. 61, 427–436 (2013).

    Article  CAS  PubMed  Google Scholar 

  14. Kong, A. et al. Detection of sharing by descent, long-range phasing and haplotype imputation. Nat. Genet. 40, 1068–1075 (2008).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Styrkarsdottir, U. et al. Nonsense mutation in the LGR4 gene is associated with several human diseases and other traits. Nature 497, 517–520 (2013).

    Article  CAS  PubMed  Google Scholar 

  16. McLaren, W. et al. Deriving the consequences of genomic variants with the Ensembl API and SNP Effect Predictor. Bioinformatics 26, 2069–2070 (2010).

    CAS  PubMed  PubMed Central  Google Scholar 

  17. Sveinbjornsson, G. et al. Weighting sequence variants based on their annotation increases power of whole-genome association studies. Nat. Genet. 48, 314–317 (2016).

    Article  CAS  PubMed  Google Scholar 

  18. Sherry, S.T. et al. dbSNP: the NCBI database of genetic variation. Nucleic Acids Res. 29, 308–311 (2001).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Bowden, J., Davey Smith, G. & Burgess, S. Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. Int. J. Epidemiol. 44, 512–525 (2015).

    Article  PubMed  PubMed Central  Google Scholar 

  20. Gudnason, V., Sigurdsson, G., Nissen, H. & Humphries, S.E. Common founder mutation in the LDL receptor gene causing familial hypercholesterolaemia in the Icelandic population. Hum. Mutat. 10, 36–44 (1997).

    Article  CAS  PubMed  Google Scholar 

  21. Brunham, L.R. & Hayden, M.R. Human genetics of HDL: insight into particle metabolism and function. Prog. Lipid Res. 58, 14–25 (2015).

    Article  CAS  PubMed  Google Scholar 

  22. Whitfield, A.J., Barrett, P.H.R., van Bockxmeer, F.M. & Burnett, J.R. Lipid disorders and mutations in the APOB gene. Clin. Chem. 50, 1725–1732 (2004).

    Article  CAS  PubMed  Google Scholar 

  23. Berbée, J.F.P., van der Hoogt, C.C., Sundararaman, D., Havekes, L.M. & Rensen, P.C.N. Severe hypertriglyceridemia in human APOC1 transgenic mice is caused by apoC-I–induced inhibition of LPL. J. Lipid Res. 46, 297–306 (2005).

    Article  PubMed  Google Scholar 

  24. Tontonoz, P. & Mangelsdorf, D.J. Liver X receptor signaling pathways in cardiovascular disease. Mol. Endocrinol. 17, 985–993 (2003).

    Article  CAS  PubMed  Google Scholar 

  25. Emerging Risk Factors Collaboration. Major lipids, apolipoproteins, and risk of vascular disease. J. Am. Med. Assoc. 302, 1993–2000 (2009).

  26. Würtz, P. et al. Lipoprotein subclass profiling reveals pleiotropy in the genetic variants of lipid risk factors for coronary heart disease: a note on Mendelian randomization studies. J. Am. Coll. Cardiol. 62, 1906–1908 (2013).

    Article  PubMed  Google Scholar 

  27. Rohatgi, A. et al. HDL cholesterol efflux capacity and incident cardiovascular events. N. Engl. J. Med. 371, 2383–2393 (2014).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Helgason, A., Nicholson, G., Stefánsson, K. & Donnelly, P. A reassessment of genetic diversity in Icelanders: strong evidence from multiple loci for relative homogeneity caused by genetic drift. Ann. Hum. Genet. 67, 281–297 (2003).

    Article  CAS  PubMed  Google Scholar 

  29. Clarke, R. et al. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N. Engl. J. Med. 361, 2518–2528 (2009).

    Article  CAS  PubMed  Google Scholar 

  30. Bennet, A.M. et al. Association of apolipoprotein E genotypes with lipid levels and coronary risk. J. Am. Med. Assoc. 298, 1300–1311 (2007).

    Article  CAS  Google Scholar 

  31. Friedewald, W.T., Levy, R.I. & Fredrickson, D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin. Chem. 18, 499–502 (1972).

    CAS  PubMed  Google Scholar 

  32. Joint International Society and Federation of Cardiology/World Health Organization Task Force on Standardization of Clinical Nomenclature. Nomenclature and criteria for diagnosis of ischemic heart disease. Circulation 59, 607–609 (1979).

  33. Scanlon, P.J. et al. ACC/AHA guidelines for coronary angiography: executive summary and recommendations. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Coronary Angiography) developed in collaboration. Circulation 99, 2345–2357 (1999).

    Article  CAS  PubMed  Google Scholar 

  34. Wetzels, J.F.M., Kiemeney, L.A., Swinkels, D.W., Willems, H.L. & den Heijer, M. Age- and gender-specific reference values of estimated GFR in Caucasians: the Nijmegen Biomedical Study. Kidney Int. 72, 632–637 (2007).

    Article  CAS  PubMed  Google Scholar 

  35. Azizi, F. et al. Prevention of non-communicable disease in a population in nutrition transition: Tehran Lipid and Glucose Study phase II. Trials 10, 5 (2009).

    Article  PubMed  PubMed Central  Google Scholar 

  36. Khalili, D. et al. The incidence of coronary heart disease and the population attributable fraction of its risk factors in Tehran: a 10-year population-based cohort study. PLoS One 9, e105804 (2014).

    Article  PubMed  PubMed Central  Google Scholar 

  37. Helgadottir, A. et al. A common variant on chromosome 9p21 affects the risk of myocardial infarction. Science 316, 1491–1493 (2007).

    Article  CAS  PubMed  Google Scholar 

  38. Kutyavin, I.V. et al. A novel endonuclease IV post-PCR genotyping system. Nucleic Acids Res. 34, e128 (2006).

    Article  PubMed  PubMed Central  Google Scholar 

  39. Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows–Wheeler transform. Bioinformatics 25, 1754–1760 (2009).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Kong, A. et al. Parental origin of sequence variants associated with complex diseases. Nature 462, 868–874 (2009).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Steinthorsdottir, V. et al. Identification of low-frequency and rare sequence variants associated with elevated or reduced risk of type 2 diabetes. Nat. Genet. 46, 294–298 (2014).

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

The authors thank all the individuals who participated in this study and whose contribution made this work possible. We also thank our valued colleagues who contributed to the data collection and phenotypic characterization of clinical samples as well as to the genotyping and analysis of the whole-genome association data. Funding was provided by deCODE Genetics/Amgen and at Emory by NIH grants UL1RR025008 from the Clinical and Translational Science Award program, R01HL089650-02, and Emory Neuroscience NINDS Core Facilities grant P30NS055077.

Author information

Authors and Affiliations

Authors

Contributions

A.H., S.G., G. Thorleifsson, U.T., D.F.G., H.H., and K.S. conceived and designed the study. D.F.G. developed statistical tools. E.H. and G.M. contributed to bioinformatic analysis. A.S., A.M., A.J., and H.K. performed experiments. A.H., G. Thorleifsson, D.F.G., A.O., and G.S. performed statistical analysis. T.R., I.J., I.O., G.I.E., O.S., M.S.D., D.K., F.A., D.W.S., L.K., A.A.Q., A.I.L., R.S.P., S.S.H., I.J.G., V.S., and G. Thorgeirsson contributed to data acquisition. A.H., S.G., G. Thorleifsson, P.S., I.O., G. Thorgeirsson, U.T., D.F.G., H.H., and K.S. analyzed and interpreted the data. All authors reviewed and approved the manuscript. K.S. supervised the study.

Corresponding authors

Correspondence to Hilma Holm or Kari Stefansson.

Ethics declarations

Competing interests

A.H., S.G., G. Thorleifsson, E.H., A.S., A.M., A.J., H.K., P.S., A.O., G.S., V.S., T.R., G.M., I.J., U.T., D.F.G., H.H. and K.S. are all employees of deCODE Genetics/Amgen, Inc.

Integrated supplementary information

Supplementary Figure 1 Pedigrees of families with APOB p.Gln725* mutation and APOB p.Gly1829Glufs8 mutation

(a,b) Pedigrees of families with APOB p.Gln725* mutation. (c) Pedigree of family with APOB p.Gly1829Glufs8 mutation. Squares denote male family members, circles denote female family members, and symbols with slashes denote deceased family members. Values below symbols are non-HDL cholesterol (above) and LDL cholesterol (below) in mmol/L for family members with available lipid information. The pedigrees have been simplified to maintain confidentiality.

Supplementary Figure 2 A schematic illustration of the lipid metabolism genes harboring mutations described in this study.

Cholesterol and triglycerides (TG) are transferred together by triglyceride-rich lipoproteins, including very low-density lipoprotein (VLDL), intermediate-density lipoproteins (IDL), chylomicrons, and chylomicron remnants. Apolipoprotein B, encoded by APOB, is an essential structural component of VLDL, IDL, LDL, and chylomicrons. The APOA1 gene encodes apolipoprotein A-I, the major protein component of HDL particles that have a key role in reverse cholesterol transport. Apolipoprotein C-I, encoded by APOC1, is associated with both HDL and triglyceride-rich lipoproteins, inhibits cholesteryl ester transfer protein (CETP), and hinders hepatic clearance of triglyceride-rich lipoproteins. ATP-binding cassette transporter (ABCA1) mediates the efflux of cholesterol and phospholipids to lipid-poor apolipoprotein A-1 to form nascent pre-β-HDL. Triglycerides from triglyceride-rich lipoproteins are hydrolyzed into free fatty acids by lipoprotein lipase (LPL). Angiopoietin-like 3 (encoded by the ANGPTL3 gene) inhibits LPL. CETP and hepatic lipase (encoded by LIPC) are central in lipoprotein remodeling. CETP facilitates transfer of cholesteryl ester (CE) from HDL to triglyceride-rich lipoproteins in exchange for triglycerides. Hepatic lipase (LIPC) remodels large lipoprotein particles into smaller and denser particles. IDL is converted to LDL by the action of hepatic lipase (LIPC). LDL is taken up by liver and other tissues in an endocytotic process that involves the LDL receptor (LDLR). Liver X receptor, encoded by the NR1H3 gene, is a cholesterol sensor that induces transcription of multiple genes that protect cells from cholesterol overload.

Supplementary information

Supplementary Text and Figures

Supplementary Figures 1 and 2, and Supplementary Note. (PDF 670 kb)

Supplementary Table 1

The association of rare and low-frequency coding variants with lipid traits, with and without covariate adjustment. (XLSX 23 kb)

Supplementary Table 2

The association of rare and low-frequency variants with blood lipids and coronary artery disease. (XLSX 16 kb)

Supplementary Table 3

Replication of the lipid association signals in populations from the Netherlands and Iran. (XLSX 17 kb)

Supplementary Table 4

The association of APOC3 loss-of-function mutations with coronary artery disease. (XLSX 10 kb)

Supplementary Table 5

Summary-level Mendelian randomization of lipid fractions and CAD using modified methods proposed by Do et al. (XLSX 11 kb)

Supplementary Table 6

Summary-level Mendelian randomization of lipid fractions and CAD extending the framework proposed by Bowden et al. to include multiple exposures. (XLSX 11 kb)

Supplementary Table 7

The total number of Icelandic individuals used in the study for each trait. (XLSX 10 kb)

Supplementary Table 8

The association of modified genetic risk scores with coronary artery disease. (XLSX 10 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Helgadottir, A., Gretarsdottir, S., Thorleifsson, G. et al. Variants with large effects on blood lipids and the role of cholesterol and triglycerides in coronary disease. Nat Genet 48, 634–639 (2016). https://doi.org/10.1038/ng.3561

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ng.3561

This article is cited by

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing